Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2010

View Archived Issues

Nerviano Medical Sciences discloses new HSP 90 inhibitors

Merck KGaA identifies new series of Sgk1 inhibitors

Roche discloses new vasopressin V1A receptor antagonists

MGMTP140K-modified CD34+ stem cells efficiently engrafted into patients with glioblastoma

UCB presents novel PI3K inhibitors

Servier discovers novel melatonin receptor ligands

Armodafinil evaluated in healthy subjects and in patients with excessive sleepiness

CSPG4 may represent prognostic biomarker for chordoma

R-7160 evaluated in phase I/II trial in solid tumors

Cook Medical submits PMA for paclitaxel-eluting stent to FDA

FDA grants orphan status to ImmunoCellular's ICT-107 vaccine for GBM

Telormedix begins phase I/II TMX-101 trial in non-muscle-invasive bladder cancer

ProSavin is safe and improves motor scores in Parkinson's disease

Upsher-Smith Laboratories initiates phase III USL-255 trial

UCB launches new oral solution of antiepileptic drug Vimpat

Phase III NExUS trial of sorafenib in NSCLC does not meet primary endpoint

FDA issues complete response letter to GSK for MenHibrix vaccine

Esperion and Cleveland Clinic to collaborate on HDL therapies for cardiovascular disease

Takeda receives pricing approval for Nesina in Japan

Faron and Priaxon to develop new AOC3/SSAO antagonists

FDA gives preliminary feedback on HGS' Zalbin BLA for chronic hepatitis C

Agile Therapeutics secures funds to advance AG-200-15 and AG-1000

FDA continues safety review of Benicar trial data in type 2 diabetes

FDA grants fast track status to Genzyme's alemtuzumab for MS

Almirall and Basilea join to commercialize Toctino for severe CHE

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...